At this time, subcutaneous semaglutide is approved for weight loss
Data are available for request 6 months after the indication studied has received first regulatory authorization and after primary publication acceptance, whichever is later
However, this is expected to change in the second quarter of this year when Medicare plans to begin covering Lillys and Novos GLP-1 obesity medications
Researchers found that exposure to the medication was similar across all groups compared with people with normal liver function
Physical activities with friends, creative pursuits, or simply adjusting to the reality that social gatherings do not require constant consumption are healthier approaches
In clinical trials, around 10 to 15 percent of the people who take the drugs are considered non-responders because they did not lose at least 5 percent of their body weight